42 filings
Page 2 of 3
6-K
59sae8acpt53v40c5
27 Oct 22
Current report (foreign)
4:00pm
6-K/A
95qqxn
31 Aug 22
Current report (foreign) (amended)
12:28pm
6-K
6z1s4 1fyi5hakxh0lk
25 Aug 22
Molecular Partners Reports Corporate Highlights and H1 2022 Financials
4:31pm
6-K
qyom47rqn0tn
13 Jun 22
Current report (foreign)
6:10am
6-K
93deeshveu9d988grt
12 May 22
Current report (foreign)
4:05pm
6-K
hh8eix ai
26 Apr 22
Molecular Partners to Regain Global Rights for MP0310 from Amgen
4:05pm
6-K
bi7n14hl7efu4j
26 Apr 22
Molecular Partners Provides Update on Ensovibep Following Novartis Quarterly Earnings Call
2:05pm
6-K
3yu9ez gmoomofh587ed
14 Apr 22
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting
6:05am
6-K
wn46s hgyr6vrd4
17 Mar 22
Molecular Partners Publishes Invitation to Annual General Meeting 2022
6:10am
6-K
37o3inadesp92i9 6rq
15 Mar 22
Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021
4:30pm
6-K
fyyz8cif fzz9fci8f8n
10 Feb 22
Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of COVID-19
6:10am
6-K
202x9
18 Jan 22
Molecular Partners Finalizes License Agreement with Novartis for Ensovibep for COVID-19
6:10am
6-K
yuo1d7v2cb010yl20f7r
10 Jan 22
Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19
9:18am
6-K
2x1etb6g281l8hffq55
15 Dec 21
Current report (foreign)
1:38pm
6-K
q9yfun
14 Dec 21
Molecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology
6:10am
6-K
1l7rhd86 jt
13 Dec 21
Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies
6:10am
6-K
x6nj4z6
30 Nov 21
Molecular Partners Confirms Retained Activity of Ensovibep on the Positions Mutated in Emerging Omicron Variant of SARS-CoV-2 In Vitro
6:10am
6-K
wbyf3g75 7grs7yuhl7
16 Nov 21
Molecular Partners Provides Update from ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19
6:10am
6-K
wnr7egye
28 Oct 21
Current report (foreign)
6:11am
6-K
ammcxjx78q i1zzcr9uj
26 Aug 21
Molecular Partners Reports Corporate Highlights and Key Financials for H1 2021
6:10am